fbpx

Diagnosed with SMM, SPB, or MGUS?

Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.

Click the orange button to the right to learn more.

Non-Toxic Smoldering Multiple Myeloma (SMM) Therapies

Share Button

Pre-MM diagnosis (MGUS, SMM)? Don’t watch and wait. Undergo evidence-based, non-toxic therapies shown to kill MM-

Pre-Myeloma is comprised of 3 diagnoses- SBP, MGUS and SMM. MGUS and SMM are considered to be asymptomatic blood disorders. Though pre-myeloma patients are usually told to “watch and wait” there is more pressure on the SMM patient to act then an MGUS patient. The MGUS patient has a 1% chance of progressing to full-blown multiple myeloma. This is compared to the SMM patient who has a 10% chance of progressing to MM annually. Further, “high-risk SMM” has an even greater risk of progression to MM.

  • Single Bone Plasmacytoma (SBP)
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Smoldering Multiple Myeloma (SMM)

Pre-MM at a glance- click the image below-

MGUS png Mind Map

The challenge for the Smoldering Multiple Myeloma patient is that his/her pre-myeloma will probably become full-blown multiple myeloma. If the Smoldering Multiple Myeloma patient is considered to be high-risk then it is only a matter of time.

Fortunately there are evidence-based, non-toxic therapies for SBP, MGUS and Smoldering Multiple Myeloma patient shown to reduce the risk of progression to frank MM.

The two studies linked and excerpted below cite two therapies for their ability to kill MM. Both intravenous vitamin C as well as curcumin have been shown to fight MM.

I reached complete remission from my own MM in early ’99 and have followed an evidence-based but non-toxic anti-MM lifestyle (nutrition, supplementation, exercise, enzymes, detox. etc.) since then.

To learn more about these evidence-based therapies, please watch the short video below:

Click here to get the FREE Pre-Myeloma Introduction Guide and follow along.

Click here to get the FREE Pre-Myeloma First Questions Guide.

 

The study linked and excerpted below cites intravenous vitamin C or ascorbic acid to selectively kill both MM and Smoldering Multiple Myeloma cells in patients while leaving normal cells unharmed. Further, the evidence-based, non-toxic therapies outlined in the Pre-Myeloma Cancer Coaching Guides also 1) reduce the risk of MM, 2) enhance bone health 3) improve the mind-body health of newly diagnosed patients.

Do you have either SBP, MGUS or Smoldering Multiple Myeloma? Are you experiencing symptoms such as bone pain, anemia or kidney damage? Please scroll down the page, post a question or a comment and I will reply to you ASAP.

Thank you,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:


Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid

” We show that pharmacologically-dosed ascorbic acid (PAA), in the presence of iron, leads to the formation of highly reactive oxygen species (ROS) resulting in cell death. PAA selectively kills CD138+ MM tumor cells derived from MM and smoldering MM  but not from monoclonal gammopathy undetermined significance (MGUS) patients…

In the 1970s, Cameron and Pauling reported that high doses of vitamin C increased survival of patients with cancer (Cameron and Pauling, 1976 ;  Cameron and Pauling, 1978). Recently, reports have shown that pharmacologically dosed ascorbic acid (PAA) 50–100 g…

Curcumin Gets Positive Results in Small MGUS and Smoldering Study

“Curcumin is beneficial to MGUS/SMM patients according to a small study published April 29 in the journal Hematology and Medical Oncology

Curcumin is the most active ingredient in a perennial herb called ‘turmeric’.  It is sold over-the-counter in capsule form, but to be effective earlier studies recommend that it be combined with an ingredient to increase its absorption into the blood stream.  Several products are available that advertise increased bioavailability.

The article concludes with:

“Our data suggest that curcumin administration may benefit some patients diagnosed with MGUS or SMM with little or no toxicity even after 9 years of therapy. Future studies should assess the role of curcumin in both MGUS and SMM patients – prior to progression to high risk or active myeloma – as this may lead to a delay in or may even stop disease progression. Although one patient has progressed to amyloidosis, the other twelve have maintained stable disease with no clear evidence of disease progression. Patient tolerance has been good and none have developed clinical infections. The drawback of this correspondence is the small number of patients on long-term curcumin therapy.””

Leave a Comment:

1 comment
Add Your Reply